Welcome to our dedicated page for agilon health SEC filings (Ticker: AGL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
agilon health, inc. filings document the company’s value-based healthcare services business, governance matters, capital structure and operating results. Form 8-K reports furnish quarterly and annual financial results, Regulation FD investor presentation materials, executive appointment and compensation arrangements, and material definitive agreements, including amendments to the company’s credit agreement.
Definitive proxy statements cover shareholder voting matters, board governance and executive compensation. The filing record also includes capital-structure disclosures, such as a certificate amendment related to a reverse stock split of common stock, along with risk-factor and material-event disclosures relevant to agilon’s physician-partnership model and payor contracting environment.
agilon health, inc. filed an initial Form 3 for Timothy Patrick O'Rourke, who is identified as CEO & President and a director. This filing establishes his status as a reporting person for agilon health under SEC rules. The data shown does not report any purchases, sales, gifts, tax withholdings, derivative exercises, or other transactions, and lists no derivative positions or holding entries at this time.
agilon health reported a much stronger first quarter of 2026, with total revenues of $1.42 billion, down 7% year over year, but profit metrics improving sharply. Gross profit rose to $65 million from $51 million, and net income increased to $48.9 million from $12.1 million, helped by higher medical margin and discontinued operations gains.
Medical margin reached $149 million, up from $128 million, and Adjusted EBITDA climbed to $53.8 million from $20.6 million. Membership on the platform declined 11% to 536,000, reflecting prior market and payor exits. Despite lower membership, agilon raised full‑year 2026 guidance for total revenues, medical margin, and Adjusted EBITDA, indicating confidence in its value‑based care model and contracting strategy.
agilon health, inc. appointed Tim O’Rourke as Chief Executive Officer, President and a Class III director, with his employment expected to begin on May 7, 2026. He succeeds Executive Chairman Ronald A. Williams, who will remain Chairman of the Board.
O’Rourke brings more than 25 years of healthcare experience, including senior roles at Help at Home, Humana, Centene and Ascension Complete. Under his Employment Agreement, he will receive a base salary of $850,000, target annual bonus equal to 100% of salary, and a $500,000 signing bonus subject to repayment if he departs under certain circumstances within one year.
He will be granted 120,000 time-vesting RSUs over three years and 200,000 PSUs that vest in three tranches if the Company’s stock achieves 30-day weighted average prices of $50, $100 and $150 during a three-year performance period, subject to continued employment. If terminated without cause or he resigns for good reason, he may receive 18 months of salary, a target bonus amount, extended medical coverage and partial acceleration of equity, with enhanced terms following a change in control.
agilon health, inc. will hold a virtual 2026 Annual Meeting on June 2, 2026, where stockholders will vote on electing three Class II directors, ratifying Ernst & Young as auditor, and approving executive pay on an advisory basis. The Board recommends voting FOR all three proposals. The company highlights its Total Care Model for Medicare seniors, noting about 75% of patients are in 4+ STAR Medicare Advantage plans and an average 4.2 Stars for 2026 ratings. For 2025, agilon reported $5.93 billion in revenue, a medical margin loss of $56.6 million, and a Reported Adjusted EBITDA loss of $296.2 million, and describes transformation initiatives and leadership changes, including an Executive Chairman structure and interim co-principal executive officers.
agilon health, inc. Chief Legal Officer Denise Zamore reported routine share dispositions related to taxes, not open-market sales. On two dates, a total of 240 shares of common stock were withheld by the company to cover income tax obligations from restricted stock unit net settlements.
After these tax-withholding transactions, Zamore directly holds 66,597 shares of agilon health common stock. The footnotes clarify that these entries reflect shares withheld by the issuer to satisfy tax and remittance obligations and “do not represent a sale.”
agilon health, inc. Chief Technology Officer Venkatachaliah Girish reported two small tax-related share dispositions through share withholding, not open-market sales. On April 15, 330 shares of Common Stock were withheld at $26.88 per share, and on April 14, 96 shares were withheld at $22.68 per share.
According to the footnotes, these shares were withheld by the issuer to satisfy income tax withholding and remittance obligations in connection with the net settlement of restricted stock units and do not represent sales. After these transactions, Girish directly holds 38,236 shares of Common Stock, and this amount includes restricted stock units.
agilon health, inc. Chief Accounting Officer Timothy Gertsch reported two Form 4 transactions in Common Stock. On April 15, 2026, 122 shares were withheld at $26.88 per share, and on April 14, 2026, 25 shares were withheld at $22.68 per share to satisfy tax obligations from restricted stock unit settlements. These transactions did not involve open-market sales, and Gertsch held 14,177 shares of Common Stock directly after the most recent transaction.
agilon health, inc. Chief Markets Officer Benjamin Shaker reported two small share dispositions that were solely for tax withholding. On April 15, 2026, 571 shares of Common Stock were withheld at $26.88 per share, leaving 122,850 shares held directly. On April 14, 2026, 104 shares were withheld at $22.68 per share, after which he held 123,421 shares. A footnote explains these were shares withheld by the issuer to satisfy income tax obligations in connection with net settlement of restricted stock units and do not represent open-market sales.